Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
The visual fatigue and visually induced motion sickness of a Virtual Reality application for pediatric amblyopia therapy
Author Affiliations & Notes
  • Yuichi Okumura
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Masakazu Hirota
    Department of Orthoptics, Teikyo Daigaku, Itabashi-ku, Tokyo, Japan
    Department of Ophthalmology, Teikyo Daigaku, Itabashi-ku, Tokyo, Japan
  • Akie Midorikawa-Inomata
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Hospital Administration, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Ken Nagino
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • takashi negishi
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Ophthalmology, Teikyo Daigaku, Itabashi-ku, Tokyo, Japan
  • Eiji Ogawa
    InnoJin, Inc, Japan
  • Shintaro Nakao
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Takenori Inomata
    Department of Ophthalmology, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
    Department of Digital Medicine, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yuichi Okumura InnoJin, Inc., Code E (Employment), Johnson & Johnson., FUKOKU Co., Ltd, Code F (Financial Support), InnoJin, Inc., Code P (Patent); Masakazu Hirota InnoJin, Inc., Code E (Employment); Akie Midorikawa-Inomata InnoJin, Inc., Code E (Employment); Ken Nagino InnoJin, Inc., Code E (Employment); takashi negishi None; Eiji Ogawa InnoJin, Inc., Code E (Employment); Shintaro Nakao Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma K.K., Code F (Financial Support); Takenori Inomata Santen Pharmaceutical Co., Ltd., Code C (Consultant/Contractor), InnoJin, Inc., Code E (Employment), Novartis Pharma KK, Santen Pharmaceutical Co., Ltd., Lion Corporation, SEED Co., Ltd., Johnson & Johnson, Shin Nippon Biomedical Laboratories, Ltd., IBM Japan, Ltd., Code F (Financial Support), Renatech Co., Ltd., InnoJin Inc., Code P (Patent)
  • Footnotes
    Support  AMED Grant 22he2722007j0001
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5429. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuichi Okumura, Masakazu Hirota, Akie Midorikawa-Inomata, Ken Nagino, takashi negishi, Eiji Ogawa, Shintaro Nakao, Takenori Inomata; The visual fatigue and visually induced motion sickness of a Virtual Reality application for pediatric amblyopia therapy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5429.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aimed to evaluate visual fatigue and visually induced motion sickness (VIMS) after using the Virtual Reality application (VR-app) for the pediatric amblyopia therapy.

Methods : The VR-app was developed based on Ken-dama, a Japanese traditional cup-and-ball game that assesses motor control and balance. This study recruited 20 healthy subjects (25.4±6.1 years old) between February 2023 and June 2023. The participants played Ken-dama using the VR-app for 30 minutes. Participants were conducted 5-point fatigue questionnaire of subjective fatigue (Q1 eye fatigue, Q2 blurred vision and diplopia, Q3 eye dryness and heaviness of eyelids, Q4 shoulder stiffness, Q5 neck fatigue, Q6 headache, Q7 sleepiness, Q8 wrist and arm fatigue, and Q9 VIMS).

Results : Subjective ocular symptoms (Q1-3) and VIMS (Q9) were not significantly different before and after playing the VR-app (Q1; 1.08 ± 1.11 vs. 1.08 ± 0.86, P > 0.990, Q2; 0.58 ± 0.49 vs. 0.67 ± 0.47, P = 0.570, Q3; 0.75 ± 0.72 vs. 1.17 ± 0.99, P = 0.083, Q9; 0.00 ± 0.00 vs. 0.00 ± 0.00, P > 0.990). In subjective general symptoms (Q4-8), stiff shoulders (0.95±0.59 vs. 1.90 ± 1.18 ; P = 0.032) and tired wrists and arms (0.30 ±0.46 vs. 2.60 ±1.11 ; P < 0.001) were significantly increased after playing the VR-app.

Conclusions : Playing the VR-app for 30 minutes was found to exacerbate shoulder stiffness and wrist and arm fatigue, but not increase subjective eye fatigue and VIMS.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×